X-linked Hypophosphatemia (XLH)
Also known as: XLH / X-Linked Hypophosphatemia / X-linked hypophosphataemia / X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) / XLHED / X Linked Hypohidrotic Ectodermal Dysplasia / X-Linked Hypohidrotic Ectodermal Dysplasia / Rickets, X-Linked Hypophosphatemic / Vitamin D-Resistant Rickets, X-Linked / Familial x-linked hypophosphatemic vitamin D refractory rickets (disorder) / Familial hypophosphatemia / Vit D resistant rickets / Acquired Vitamin D-Resistant Rickets / Rickets (vitamin D resistant) / Rickets - vitamin D resistant / Hereditary hypophosphataemic rickets / Hereditary hypophosphatemic rickets / Vitamin D-dependent rickets, type 2 (disorder) / Rickets familial hypophosphataemic / Familial hypophosphataemic rickets / Familial hypophosphatemic rickets / Rickets familial hypophosphatemic
Drug | Drug Name | Drug Description |
---|---|---|
DB14012 | Burosumab | A fibroblast growth factor 23 blocking antibody used to treat X-linked hypophosphatemia. |
Drug | Drug Name | Target | Type |
---|---|---|---|
DB14012 | Burosumab | Fibroblast growth factor 23 | target |
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB00136 | Calcitriol | 0 | Recruiting | 1 |
DB14523 | Phosphate ion | 0 | Suspended | 1 |
DB14012 | Burosumab | 1 | Completed | 1 |
DB18188 | EDI-200 | 1 | Completed | 1 |
DB14012 | Burosumab | 1 / 2 | Active Not Recruiting | 1 |
DB14012 | Burosumab | 1 / 2 | Completed | 2 |
DB14012 | Burosumab | 2 | Completed | 3 |
DB18188 | EDI-200 | 2 | Completed | 1 |
DB14012 | Burosumab | 3 | Completed | 6 |
DB11094 | Vitamin D | 3 | Completed | 1 |
DB14012 | Burosumab | 4 | Active Not Recruiting | 2 |
DB14012 | Burosumab | 4 | Completed | 1 |
DB14012 | Burosumab | 4 | Unknown Status | 1 |
DB00136 | Calcitriol | 4 | Recruiting | 1 |
DB14151 | Phosphorus | 4 | Recruiting | 1 |
DB14012 | Burosumab | Not Available | Available | 1 |
DB14012 | Burosumab | Not Available | Recruiting | 1 |
DB18188 | EDI-200 | Not Available | Active Not Recruiting | 1 |